Larimar Therapeutics, Inc.
LRMR
$0.05
Change (1 day)
$13.68
Year High
$3.19
Year Low
Categories
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Earnings for Larimar Therapeutics, Inc. (LRMR)
Earnings in 2023 (TTM): $-36,949,000
According to Larimar Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-36,949,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Larimar Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-36,949,000 | $-36,949,000 |
| 2022 | $-35,355,000 | $-34,184,000 |
| 2021 | $-50,636,000 | $-50,310,000 |
| 2020 | $-42,482,000 | $-42,327,000 |
| 2019 | $-23,132,000 | $-23,132,000 |
| 2018 | $-62,968,000 | $-61,368,000 |
| 2017 | $-52,928,000 | $-52,028,000 |
| 2016 | $-58,178,000 | $-57,878,000 |
| 2015 | $-74,286,000 | $-74,286,000 |
| 2014 | $-36,570,000 | $-36,570,000 |